Assuming IDE approved, $5 certainly possible at some point but who knows when? Maybe in a volume fomo pop upon IDE approval before next offering? But I'm thinking would need positive human trial data to sustain price near $5. At that point RDGL would be a buyout play. Too far down road for me to worry about. I'm still looking to exit upon IDE approval and not looking beyond that. Might consider buying back in after the dust settles post IDE.